Aldeyra Therapeutics, Inc.
Symbol: ALDX (NASDAQ)
4.93
▼ (-1.70%) -0.085
Company Description:
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Key Stats
- Today's Open: $5.05
- Today's High: $5.105
- Today's Low: $4.785
- Today's Volume: 1.50M
- Yesterday Close: $5.01
- Yesterday High: $5.105
- Yesterday Low: $4.94
- Yesterday Volume: 746.54K
- Last Min Volume: 0
- Last Min High: $4.925
- Last Min Low: $4.912
- Last Min VWAP: $0
Company Profile
- Name: Aldeyra Therapeutics, Inc.
- Website: https://www.aldeyra.com
- Listed Date: 2014-05-02
- Location: LEXINGTON, MA
- Market Status: Active
- CIK Number: 0001341235
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $296.02M
- Round Lot: 100
- Outstanding Shares: 60.05M
- Asset Type: CS
RECENT FILINGS FOR ALDX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-19 | 8-K | View |
| 2025-08-15 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 4 | View |
| 2025-08-12 | 144 | View |
| 2025-08-07 | 10-Q | View |
| 2025-07-17 | 8-K | View |
| 2025-06-26 | 8-K | View |
| 2025-06-17 | 8-K | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-11 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-06 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
Latest News on ALDX